Change in Bone Scan Index Predicts Prostate CA Survival

This article originally appeared here.
Share this content:
Change in Bone Scan Index Predicts Prostate CA Survival
Change in Bone Scan Index Predicts Prostate CA Survival

(HealthDay News) – On-treatment related change in the bone scan index (BSI) is strongly associated with survival in patients receiving chemotherapy for metastatic prostate cancer, according to a study published online January 9 in the Journal of Clinical Oncology.

Elizabeth R. Dennis, of the Memorial Sloan-Kettering Cancer Center in New York City, and colleagues retrospectively examined serial bone scans from 88 patients with castration-resistant metastatic prostate cancer who were enrolled in four clinical trials. BSI was calculated at baseline and at three and six months on treatment, and the change in BSI was evaluated with respect to survival and compared with prostate-specific antigen (PSA) as an outcome measure.

The researchers found that, in the univariate analysis, survival was predicted by the log percent change in BSI from baseline to three and six months on treatment (hazard ratio [HR], 2.44 and 2.54, respectively), with a doubling in BSI resulting in a 1.9-fold elevated risk of death. At six months of treatment, the log percent change in PSA was also associated with survival (HR, 1.298). In the bivariate analysis, when adjusting for PSA, a change in BSI was prognostic at three and six months on treatment (HR, 2.368 and 2.226, respectively), but PSA was not prognostic when adjusting for BSI.

"These data furnish early evidence that on-treatment changes in BSI are a response indicator and support further exploration of bone scintigraphy as an imaging biomarker in castration-resistant metastatic prostate cancer," the authors write.

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs